The final results of the MASAI study, published in The Lancet and covered by major international media outlets such as The Guardian, mark a turning point in oncological diagnostics. The randomized trial, involving over 100,000 women in Sweden, demonstrates that integrating AI into the screening workflow is not only safe, but superior to traditional methods.
According to the published evidence, the use of AI led to a 12% reduction in interval cancers—that is, cancers that emerge between screening rounds because they were not initially detected—while also achieving a 44.3% reduction in radiologists’ workload.
The algorithm acts as an intelligent filter: it accurately identifies negative cases, allowing physicians to focus their clinical expertise on more complex and uncertain diagnostic scenarios.
This model is no longer just a theoretical frontier, but a concrete response to the growing pressure on healthcare systems and the shortage of specialists. In Italy, where managing invitations within screening programs remains challenging, these findings support the recent updates to the National Institute of Health (ISS) guidelines.
Health Triage’s commitment in Italy
Within this evolving landscape, Health Triage is working to translate international research findings into operational solutions for the Italian National Health Service. Through its medical device BreastNegative (MDR Class IIb certified), a new prospective multicenter clinical study involving 75,000 women is about to begin in collaboration with GISMa (Italian Mammography Screening Group).
The system is designed to rapidly identify negative exams—which represent the vast majority of screenings—thereby optimizing the entire reporting workflow.
“As clearly shown by the MASAI trial results published in The Lancet, AI proves to be a key ally for radiologists, not a replacement,” explains Davide Dettori CEO of Health Triage.
“Our goal is to provide tools capable of quantifying diagnostic uncertainty, freeing up valuable clinical time and enabling specialists to focus on cases that require deeper analysis.”
Partnerships and Innovation
Looking ahead, AI in medical imaging is expected to grow structurally. Health Triage, supported by Petrone Group and Fondazione ENEA Tech e Biomedical, is ready to translate these scientific findings into scalable, real-world solutions for public healthcare.
Prevention thus becomes more timely and precise, thanks to a technology designed to support both physicians and patients.
Informational note
BreastNegative is an MDR Class IIb certified medical device. The technology is intended as a decision-support tool, and final diagnostic responsibility remains exclusively with the specialist physician.
